Drug Recall Alert: High Blood Pressure Medication Contaminated

Glenmark Pharmaceuticals recalls over 11,100 bottles of Ziac due to potential cholesterol drug contamination

Apr. 11, 2026 at 10:46am

Got story updates? Submit your updates here. ›

An extreme close-up of a glowing, neon-outlined pill bottle against a dark background, conceptually representing the issue of medication contamination and the importance of safety in the healthcare industry.The voluntary recall of a contaminated blood pressure medication highlights the need for stringent quality control in the pharmaceutical industry.Elmwood Park Today

Glenmark Pharmaceuticals, a pharmaceutical company based in Elmwood Park, New Jersey, has voluntarily recalled over 11,100 bottles of its high blood pressure medication Ziac due to a potential contamination issue. The FDA's investigation revealed that the recalled batches may contain traces of ezetimibe, a drug typically used to manage high cholesterol. While the FDA has classified this as a Class III recall, indicating a low risk of adverse health effects, the presence of an unintended substance raises concerns for patients with specific health conditions or sensitivities.

Why it matters

Even a Class III recall can have serious implications for patients, as the presence of an unintended substance in a medication can pose risks for those with certain health conditions or sensitivities. This incident highlights the importance of stringent quality control measures in the pharmaceutical industry and the need for transparency and proactive action by manufacturers to protect public health.

The details

The affected bottles of Ziac, in 2.5 mg and 6.25 mg doses, were set to expire between November 2025 and May 2026. The FDA has provided the following package details to help identify the recalled products: 30-count bottles with NDC 68462-878-30, 100-count bottle with NDC-68462-878-01, and 500-count bottles with NDC68462-878-05. Patients who have any of these recalled batches are advised to consult their healthcare providers for guidance.

  • The recall was announced on April 11, 2026.
  • The affected bottles were set to expire between November 2025 and May 2026.

The players

Glenmark Pharmaceuticals

A pharmaceutical company based in Elmwood Park, New Jersey, that has voluntarily recalled over 11,100 bottles of its high blood pressure medication Ziac due to a potential contamination issue.

U.S. Food and Drug Administration (FDA)

The regulatory agency that classified the recall as Class III, indicating a low risk of adverse health effects, and provided details on the affected product batches.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain vigilant in ensuring the safety and quality of all medications, as even a seemingly minor issue can have serious consequences for patients.”

— Dr. Sarah Wilkins, Pharmacologist

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights the critical importance of robust quality control measures in the pharmaceutical industry, as well as the need for transparent communication and proactive action by manufacturers to protect public health. It serves as a reminder that even seemingly minor issues with medication can have significant implications for patients, particularly those with specific health conditions or sensitivities.